Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 7:64:633-640.
doi: 10.2340/1651-226X.2025.42498.

Clinical characteristics and treatment outcome in p16 negative anal cancer

Affiliations

Clinical characteristics and treatment outcome in p16 negative anal cancer

Catherine Burgos et al. Acta Oncol. .

Abstract

Background: Anal squamous cell carcinoma (ASCC) is linked to human papillomavirus infection with p16 being positive in about 85% of cases. Overall survival (OS) of ASCC is 60%-80%. Prognosis in p16 negative (p16-) ASCC is worse with an OS of 30%-60%. It is important to elucidate differences in p16+ and p16- ASCC characteristics and outcome.

Methods: Consecutive ASCC patients (n = 380) treated with curative intent in Uppsala 2017-2022 were reviewed and analyzed retrospectively. A cohort of p16- patients (n = 30) from Gothenburg was included as a validation cohort.

Results: Ninety-one per cent (n = 347) were p16+ and 9% (n = 33) p16-. Median follow-up was 33 months (range 4-78). p16- status was associated with higher age (≥65 years; p = 0.03), comorbidity (p = 0.03), male sex (p = 0.001) and perianal localization (p < 0.001). At 3 years progression free survival was 50% and 81% (p <0.0001) and OS 60% and 89% (p < 0.0001) for p16- and p16+ patients, respectively. Male sex, advanced T-stage (T3-4), N+ disease, advance treatment and p16- status were associated with inferior OS (p = 0.01 - p < 0.0001). In the p16- subgroup, advanced T-stage and intensive treatment were negative prognostic factors for OS (p = 0.007 and 0.009, respectively) but no clinical characteristic predicted persistent disease. The p16- validation cohort essentially confirmed the findings from the main cohort.

Interpretation: p16- ASCC is a disease subset with specific clinical features and poor prognosis in need of improved treatment.

PubMed Disclaimer

Conflict of interest statement

The authors report there are no competing interests to declare.

Figures

Figure 1
Figure 1
Overall treatment outcome according to p16-status for the Uppsala cohort (n = 380). See Table 2, for details on outcome and statistical inference.
Figure 2
Figure 2
Overall survival according to p16-status with p16- patients separated for treatment center, Gothenburg cohort used as a validation cohort (a) and disease specific survival in Uppsala patients (b) and progression free survival (c) according to p16-status in Uppsala patients.

Similar articles

References

    1. Deshmukh AA, Suk R, Shiels MS, Sonawane K, Nyitray AG, Liu Y, et al. . Recent trends in squamous cell carcinoma of the anus incidence and mortality in the United States, 2001–2015. J Natl Cancer Inst. 2020;112(8):829–38. 10.1093/jnci/djz219 - DOI - PMC - PubMed
    1. Rao S, Guren MG, Khan K, Brown G, Renehan AG, Steigen SE, et al. . Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(☆). Ann Oncol. 2021;32(9):1087–100. 10.1016/j.annonc.2021.06.015 - DOI - PubMed
    1. Frisch M, Glimelius B, Van den Brule AJC, Wohlfahrt J, Meijer CJLM, Walboomers JMM, et al. . Sexually transmitted infection as a cause of anal cancer. N Engl J Med. 1997;337(19):1350–8. 10.1056/NEJM199711063371904 - DOI - PubMed
    1. Daling JR, Madeleine MM, Johnson LG, Schwartz SM, Shera KA, Wurscher MA, et al. . Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer. 2004;101(2):270–80. 10.1002/cncr.20365 - DOI - PubMed
    1. Maniar KP, Nayar R. HPV-related squamous neoplasia of the lower anogenital tract: an update and review of recent guidelines. Adv Anat Pathol. 2014;21(5):341–58. 10.1097/PAP.0000000000000035 - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources